NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Medical Distribution · USD

EDAP TMS S.A. (FOCL) Stock Analysis

EDAP TMS S.A. (FOCL) is a Medical Distribution stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

FOCL

$4.15

−$0.22 (−5.03%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FOCL with… →

FOCL Key Statistics

As of Oct 22, 2026
Trading
Open
$4.28
Previous Close
$4.37
Day's Range
4.15–4.39
52-Week Range
1.75–6.40
Volume
30.74K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.05
Valuation
Market Cap
$195.95M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.39
Financials (FY)
Revenue (FY)
$70.53M+1.63%
Net Income (FY)
−$29.25M
Profit marginThe share of revenue left as profit after all costs and taxes.
−49.13%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.22M
1-Year Return
+78.88%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
115.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, FOCL closed at $4.15, +78.88% over 1 year.

EDAP TMS S.A. (FOCL) has a market capitalization of $195.95M.

In fiscal 2025, FOCL reported revenue of $70.53M.

FOCL Stock Return by Calendar Year

EDAP TMS S.A. (FOCL) 10-year return: what $10,000 became

1 year
$10,000 $17,888
+78.88%
5 years
$10,000 $6,905
−30.95%
10 years
$10,000 $15,257
+52.57%

If you had invested $10,000 in EDAP TMS S.A. (FOCL) 10 years ago, at the close on October 21, 2016, it would have been worth $15,257 at the close on October 22, 2026: +52.57% in total, +4.32% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.14%
2025+48.87%
2024−58.14%
2023−50.47%
2022+77.96%
2021+15.86%
2020+16.70%
2019+139.46%
2018−35.54%
2017−12.50%
2016 (partial year)+7.54%

As of October 22, 2026.

FOCL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$70.53M−$29.25M−41.5%
2024$69.40M−$20.58M−29.7%
2023$66.79M−$23.41M−35.0%
2022$59.10M−$3.15M−5.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$70.53M$30.00M−$24.70M−$29.25M−41.5%
2024$69.40M$28.74M−$22.23M−$20.58M−29.7%
2023$66.79M$26.98M−$21.90M−$23.41M−35.0%
2022$59.10M$25.94M−$4.57M−$3.15M−5.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FOCL Valuation vs Medical Distribution Median

Median of 11 stocks
MetricFOCLMedical Distribution medianvs median
P/S ratio2.470.357.0x the median
Profit margin−49.13%−4.73%44.4 pts below

Medians across 11 Medical Distribution stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

EDAP TMS S.A. (FOCL) is capitalised at $195.95M on the latest close. It is classified in the Medical Distribution industry, within the Healthcare sector. Headcount on file is 289.

The most recent close on file for FOCL is $4.15, dated October 22, 2026. That is −$0.22 (−5.03%) against the previous close. The 52-week range on file runs from $1.75 to $6.40. The latest close sits 137.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $70.53M. Against the prior fiscal year total of $69.40M, that is a change of +1.63%. The same year closed with a net loss of $29.25M. Profit margin runs at −49.13%. That is 44.4 percentage points below the Medical Distribution median of −4.73%. Earnings per share on a trailing basis come to −1.39.

Across the 4 fiscal years on file, revenue moves from $59.10M in 2022 to $70.53M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.47. On price-to-sales that is 7 times the Medical Distribution median of 0.35. The medians here are taken across 11 Medical Distribution companies that report the metric.

Over the trailing twelve months the total return is +78.88%. Measured over 10 years, that is +4.32% a year compounded. The reported beta is −0.05. Annualized volatility over the trailing 10 years is 65.6%.

Growth & Income

No dividend is on file for FOCL.

Across the complete calendar years on file, 2019 returned +139.46% and 2024 returned −58.14%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is +26.14% year to date.

Peer Comparison

EDAP TMS S.A. (FOCL) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
EDAP TMS S.A. FOCL $195.95M —
McKesson Corporation MCK $118.03B 27.1
Cencora, Inc. COR $64.59B 25.1
Cardinal Health, Inc. CAH $58.83B 35.1

The Medical Distribution industry average P/E ratio is 26.1x. EDAP TMS S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Medical Distribution Stocks

MCK

McKesson Corporation

$118.03B

 COR

Cencora, Inc.

$64.59B

 CAH

Cardinal Health, Inc.

$58.83B

 HSIC

Henry Schein, Inc.

$9.58B

 AHG

Akso Health Group

$1.05B

 YI

111, Inc.

$27.01M
View all Medical Distribution stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About EDAP TMS S.A.

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.

Visit website →